Cogent Biosciences (COGT) Receivables - Doubtful (2017 - 2023)
Cogent Biosciences (COGT) posted quarterly Receivables - Doubtful of $157.1 million for Q4 2023, up 75.41% year-over-year from $89.5 million in Q4 2022, and up 75.41% quarter-over-quarter from $89.5 million in Q4 2022.
Cogent Biosciences (COGT) Receivables - Doubtful (2017 - 2023) Analysis & Trends
Cogent Biosciences (COGT) has reported Receivables - Doubtful for 7 consecutive years, with $157.1 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Receivables - Doubtful rose 75.41% year-over-year to $157.1 million; the TTM figure through Dec 2023 stood at $157.1 million (up 75.41% YoY), while the FY2023 annual figure was $157.1 million, up 75.41% from the prior year.
- Receivables - Doubtful rose to $157.1 million in Q4 2023 per COGT's latest filing, from $89.5 million in the prior quarter.
- Across five years, Receivables - Doubtful topped out at $157.1 million in Q4 2023 and bottomed at $27.8 million in Q4 2020.
- Historically, Receivables - Doubtful has averaged $71.9 million across 5 years, with a median of $46.7 million in 2021.
- Annual changes were most pronounced in 2020 — Receivables - Doubtful slipped 27.77% — and 2022, when it surged 91.8%.
- Cogent Biosciences' Receivables - Doubtful stood at $38.5 million in 2019, then retreated by 27.77% to $27.8 million in 2020, then soared by 67.94% to $46.7 million in 2021, then surged by 91.8% to $89.5 million in 2022, then surged by 75.41% to $157.1 million in 2023.
- Business Quant data shows COGT's Receivables - Doubtful at $157.1 million in Q4 2023, $89.5 million in Q4 2022, and $46.7 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Doubtful (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 157.07 Mn |
| Dec 31, 2023 | 157.07 Mn |
| Dec 31, 2022 | 89.54 Mn |
| Dec 31, 2022 | 89.54 Mn |
| Dec 31, 2021 | 46.69 Mn |
| Dec 31, 2021 | 46.69 Mn |
| Dec 31, 2020 | 27.80 Mn |
| Dec 31, 2020 | 27.80 Mn |
| Dec 31, 2019 | 38.49 Mn |
| Dec 31, 2019 | 38.49 Mn |
| Dec 31, 2018 | 28.90 Mn |
| Dec 31, 2018 | 28.90 Mn |
| Dec 31, 2017 | 16.61 Mn |
| Dec 31, 2017 | 16.61 Mn |